Project Challenge:

A European biotech company was developing next-generation ADC payloads with at least as good intracellular cytotoxicity properties as other payloads used in ADCs, but with a much lower toxicity of unbound payload should any be released into the systemic circulation. The client asked Alacrita for advice on presenting the company in potential partnering discussions with CDMOs and biotech/pharma companies and on target deal structures and terms.


Project Solution:

• Re-positioning of the company's messaging and a revamp of the corporate slide deck describing the technology and value proposition;
• Modeling alternative deal structures and terms, and providing publicly available transaction benchmarks to support the client's CEO who was engaged in fundraising and partnering processes in parallel.